Accessibility Menu
GSK logo

GSK(LSE) GSK

Market Cap£76.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)+840%
5 Year+32%
1 Year+37%
1 Month-3%
£19.16
+0.05%
+0.01Today
GSK last closing stock price
MetricPriceDate
Last closeGBX 1,915.502026-08-05
GSK stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.56%GBX 2,007.002026-07-29
1 month-3.4%GBX 1,983.002026-07-06
3 month+3.07%GBX 1,858.502026-05-07
Year to date+4.99%GBX 1,824.502025-12-31
1 year+37.12%GBX 1,397.002025-08-05
3 year+42.2%GBX 1,347.002023-08-04
5 year+32.03%GBX 1,450.852021-08-06
Since inception+840.2%GBX 2.041992-01-02

GSK Financials at a Glance

Market Cap

£76.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£33.20B

Net Income (TTM)

£4.82B

EPS (TTM)

£1.18

P/E Ratio

16.00

Dividend

£0.67

Beta (Volatility)

0.02 (Low)

Price

£19.16

Volume

5,163,863

Open

£19.22

Previous Close

£19.16

Daily Range

£19.13 - £19.65

52-Week Range

£13.61 - £22.82

Estimated Earnings Date

Oct 28, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GSK

GSK plc is a global pharmaceutical and healthcare company engaged in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. With operations in the United Kingdom, the United States, and various international markets, GSK is structured across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare.

Products and Services
  • Pharmaceuticals addressing respiratory, HIV, oncology, and central nervous system disorders
  • Vaccines for various infectious diseases
  • Consumer healthcare products including oral hygiene and nutritional supplements
Growth Outlook
  • Recent quarterly revenue reached £7.63 billion, indicating strong market demand
  • TTM net income stands at £6.93 billion, reflecting robust profitability
  • Strategic collaborations with leading biotech firms enhance innovation potential
Financial Highlights
  • Dividend yield of 3.58% offers attractive returns to shareholders
  • TTM P/E ratio of 12.92 suggests potential undervaluation compared to peers
  • Operating income margin of 30.06% demonstrates efficient cost management
GSK plc operates in a competitive landscape, focusing on innovation and strategic partnerships to drive growth. The company's diverse product portfolio and strong financial performance position it well for future opportunities. Recent quarterly results highlight a solid revenue stream and profitability, while the attractive dividend yield may appeal to income-focused investors. With a commitment to research and development, GSK is poised to continue its legacy of delivering impactful healthcare solutions globally.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Employees

66,841

CEO

Luke Miels, MBA

Headquarters

London, GL WC1A 1DG, GB

GSK Financials

Key Financial Metrics (TTM)

Gross Margin

73.29%

Operating Margin

24.12%

Net Income Margin

14.52%

Return on Equity

28.35%

Return on Capital

21.03%

Return on Assets

7.81%

Earnings Yield

6.25%

Dividend Yield

3.50%

Payout Ratio

55.30%

Stock Overview

Market Cap

£76.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.01B

Volume

5.16M

Avg. Volume

8.20M

Financials (TTM)

Gross Profit

£24.33B

Operating Income

£8.01B

EBITDA

£10.95B

Operating Cash Flow

£7.98B

Capital Expenditure

-£2.22B

Free Cash Flow

£5.76B

Cash & ST Invst.

£3.11B

Total Debt

£18.24B

GSK Performance Analysis

GSK annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 29,324,000,00018.7%
20232023-12-31GBP 30,328,000,0003.4%
20242024-12-31GBP 31,376,000,0003.5%
20252025-12-31GBP 32,667,000,0004.1%
GSK sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.0%
Q42025-12-310.8%
Q12026-03-31-11.5%
Q22026-06-3010.2%
GSK annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP 3.66170.7%
20232023-12-31GBP 1.20-67.3%
20242024-12-31GBP 0.62-48.1%
20252025-12-31GBP 1.39123.3%
GSK sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3040.0%
Q42025-12-31-67.3%
Q12026-03-31168.8%
Q22026-06-30-74.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£8.41B

+5.3%

Gross Profit

£6.31B

+8.4%

Gross Margin

75.05%

N/A

Market Cap

£76.75BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£1.15M

N/A

Employees

66,841

N/A

Net Income

£435.00M

-69.9%

EBITDA

£2.62B

-18.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£3.11B

-14.2%

Total Debt

£18.24B

N/A

Accounts Receivable

£8.07B

+10.3%

Inventory

£6.28B

+3.5%

Long Term Debt

£13.95B

N/A

Short Term Debt

£4.29B

N/A

Return on Assets

7.81%

N/A

Return on Invested Capital

19.92%

N/A

Free Cash Flow

£2.20B

+50.2%

Operating Cash Flow

£2.53B

+20.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HLN.LHaleon plc
£3.66+2.24%
HIK.LHikma Pharmaceuticals PLC
£15.71-0.63%
HCM.LHUTCHMED (China) Limited
£1.78+2.89%
BXP.LBeximco Pharmaceuticals Limited
£0.53+1.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$108.27-0.14%
NVDANvidia
$219.22+0.03%
ONDSOndas
$8.87+0.00%
PATHUiPath
$13.82-0.02%

Questions About GSK

What is the current price of GSK?

GSK is trading at £19.16 per share.

What is the 52-week range for GSK?

Over the past 52 weeks, GSK has traded between £13.61 and £22.82.

How much debt does GSK have?

As of the most recent reporting period, GSK reported total debt of £18.24B.

How much cash does GSK have on hand?

GSK reported £3.11B in cash and cash equivalents in its most recent financial results.

What is GSK’s dividend yield?

GSK currently has a dividend yield of 3.50%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.